Literature DB >> 22294071

Renal Sympathetic Denervation for Treatment of Hypertension.

Eduardo Pimenta1, Suzanne Oparil.   

Abstract

OPINION STATEMENT: Sympathetic nervous system activation of the heart, kidney and peripheral vasculature increases cardiac output, fluid retention and vascular resistance and plays an important role in acute and chronic BP elevation. Renal sympathetic denervation via a percutaneous radiofrequency catheter based approach is a safe and effective procedure that lowers BP in patients with resistant hypertension. Exploratory studies in patients with resistant hypertension and a variety of comorbidities, including insulin resistance/metabolic syndrome, obstructive sleep apnea and the polycystic ovary syndrome, have shown benefit of renal denervation in attenuating the severity of the comorbid conditions, as well as reducing BP. However, more studies are needed to further address the long term effects of renal denervation and its safety and effectiveness in other disease states such as congestive heart failure.

Entities:  

Year:  2012        PMID: 22294071     DOI: 10.1007/s11936-012-0166-9

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  48 in total

Review 1.  Renal sympathetic nerve ablation: the new frontier in the treatment of hypertension.

Authors:  Markus P Schlaich; Henry Krum; Paul A Sobotka
Journal:  Curr Hypertens Rep       Date:  2010-02       Impact factor: 5.369

Review 2.  Physiology in perspective: The Wisdom of the Body. Neural control of the kidney.

Authors:  Gerald F DiBona
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2005-09       Impact factor: 3.619

Review 3.  Novel procedure- and device-based strategies in the management of systemic hypertension.

Authors:  Henry Krum; Markus Schlaich; Paul Sobotka; Ingrid Scheffers; Abraham A Kroon; Peter W de Leeuw
Journal:  Eur Heart J       Date:  2011-01-18       Impact factor: 29.983

4.  Can catheter-based renal denervation be used safely and effectively to substantially reduce blood pressure in treatment-resistant hypertensive patients?

Authors:  Suzanne Oparil
Journal:  Curr Cardiol Rep       Date:  2011-12       Impact factor: 2.931

5.  The sympathetic nervous system through the ages: from Thomas Willis to resistant hypertension.

Authors:  Murray Esler
Journal:  Exp Physiol       Date:  2011-05-06       Impact factor: 2.969

6.  Renal sympathetic denervation: a novel intervention for resistant hypertension, insulin resistance, and sleep apnea.

Authors:  Brent M Egan
Journal:  Hypertension       Date:  2011-08-15       Impact factor: 10.190

7.  Regional norepinephrine turnover in human hypertension.

Authors:  M Esler; G Lambert; G Jennings
Journal:  Clin Exp Hypertens A       Date:  1989

8.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

9.  Sympatho-renal axis in chronic disease.

Authors:  Paul A Sobotka; Felix Mahfoud; Markus P Schlaich; Uta C Hoppe; Michael Böhm; Henry Krum
Journal:  Clin Res Cardiol       Date:  2011-06-19       Impact factor: 5.460

10.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.

Authors:  Henry Krum; Markus Schlaich; Rob Whitbourn; Paul A Sobotka; Jerzy Sadowski; Krzysztof Bartus; Boguslaw Kapelak; Anthony Walton; Horst Sievert; Suku Thambar; William T Abraham; Murray Esler
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321

View more
  4 in total

1.  Effects of renal sympathetic denervation and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy. Comparison in spontaneously hypertensive rats.

Authors:  X Ding; X Xu; Y Yan; X Song; S Liu; G Wang; D Su; Q Jing; Y Qin
Journal:  Herz       Date:  2014-06-14       Impact factor: 1.443

Review 2.  Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension?

Authors:  Eduardo Pimenta; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

3.  Novel strategies for treatment of resistant hypertension.

Authors:  Eric K Judd; Suzanne Oparil
Journal:  Kidney Int Suppl (2011)       Date:  2013-12

Review 4.  The efficacy of antihypertensive drugs in chronic intermittent hypoxia conditions.

Authors:  Lucilia N Diogo; Emília C Monteiro
Journal:  Front Physiol       Date:  2014-09-22       Impact factor: 4.566

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.